Wednesday, December 12, 2018 10:51:22 PM
Publication number WO2017013498 A2
Publication type Application
Application number PCT/IB2016/001181
Publication date Jan 26, 2017
Filing date Jul 19, 2016
Priority date Jul 22, 2015
Also published as WO2017013498A3
Inventors Peter York, Lucy Anne LEONARD, Daniel Mark LEDGER, Linda Sharon Daintree
Applicant Anavex Life Sciences Corp.
Export Citation BiBTeX, EndNote, RefMan
Classifications (5), Legal Events (1)
External Links: Patentscope, Espacenet
Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions
WO 2017013498 A2
ABSTRACT
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2- diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
CLAIMS (OCR text may contain errors)
CLAIMS What is claimed is:
1. A crystalline form of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 1, FIG. 4, or FIG. 8.
2. The crystalline form of claim 1, further characterized by the FTIR spectrum shown in FIG. 5 or FIG. 9.
3. The crystalline form of claim 1, further characterized by the ^-NMR spectrum shown in FIG. 6 or FIG. 10.
4. The crystalline form of claim 1, further characterized by the particle shapes depicted in FIG. 2, FIG. 3, FIG. 7 or FIG. 11.
5. The crystalline form of claim 1, further characterized by the particle sizes depicted in FIG. 2, FIG. 3, FIG. 7 or FIG. 11.
6. The crystalline form of claim 1, wherein the habit is plate-like.
7. The crystalline form of claim 1, wherein the habit is needle-like.
The crystalline form of claim 1, wherein the habit is lath
9. A method of making the crystalline form of claim 1, wherein the method uses a supercritical fluid (SCF) technique.
10. A dosage form comprising a therapeutically neuroprotective amount of the crystalline form of claim 1.
11. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the crystalline form of any of claims 1-8.
12. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the crystalline form of any of claims 1-8.
13. Crystalline Form I of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 1.
14. The crystalline Form I according to claim 13, characterized by the particle shapes as depicted in FIG. 2.
15. The crystalline Form I according to claim 13, characterized by the particle shapes as depicted in FIG. 3.
16. The crystalline Form I according to claim 13, characterized by the particle sizes as depicted in FIG. 2.
17. The crystalline Form I according to claim 13, characterized by the particle sizes as depicted in FIG. 3.
18. The crystalline form of claim 13, wherein the habit is plate-like.
19. A method of making the crystalline form of any of claims 13-18, wherein the method uses a supercritical fluid (SCF) technique.
20. A dosage form comprising a therapeutically neuroprotective amount of the crystalline form of any of claims 13-18.
21. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the crystalline form of any of claims 13-18.
22. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the crystalline form of any of claims 13-18.
23. Crystalline Form II of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 4.
24. Crystalline Form II of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the FTIR spectrum shown in FIG. 5.
25. Crystalline Form II of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the ^-NMR spectrum shown in FIG. 6.
26. The crystalline Form II according to any of claims 23-25, characterized by particle shapes as depicted in FIG. 7.
27. The crystalline Form II according to any of claims 23-25, characterized by particle sizes as depicted in FIG. 7.
28. The crystalline Form II of any of claims 23-25, wherein the habit is plate-like.
29. A method of making the crystalline Form II of any of claims 23-28, wherein the method uses a supercritical fluid (SCF) technique.
30. A dosage form comprising a therapeutically neuroprotective amount of the crystalline Form II of any of claims 23-28.
31. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the crystalline Form II of any of claims 23-28.
32. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the crystalline Form II of any of claims 23-28.
33. Crystalline Form III of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 8.
34. Crystalline Form III of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the FTIR spectrum shown in FIG. 9.
35. Crystalline Form III of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the ^-NMR spectrum shown in FIG. 10.
36. The crystalline Form III according to any of claims 33-35, characterized by particle shapes as depicted in FIG. 11.
37. The crystalline Form III according to any of claims 33-35, characterized by particle sizes as depicted in FIG. 11.
38. The crystalline Form III of any of claims 33-35, wherein the habit is lath-like.
39. A method of making the crystalline Form III of any of claims 33-38, wherein the method uses a supercritical fluid (SCF) technique.
40. A dosage form comprising a therapeutically neuroprotective amount of the crystalline Form III of any of claims 33-38.
41. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the crystalline Form III of any of claims 33-38.
42. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the crystalline Form III of any of claims 33-38.
43. The metabolite ANAVEX19-144 characterized by the PXRD pattern shown in FIG. 12.
44. The metabolite ANAVEX19-144 characterized by the DSC-TGA data shown in FIG. 13.
45. The metabolite ANAVEX19-144 characterized by the FTIR spectrum shown in FIG. 14.
46. The metabolite ANAVEX19-144 of any of claims 43-45 characterized by particle shapes as depicted in FIG. 15.
47. The metabolite ANAVEX19-144 of any of claims 43-45 characterized by particle sizes as depicted in FIG. 15.
48. The metabolite ANAVEX19-144 of any of claims 43-45, wherein the habit is needle-like.
49. A method of making the metabolite ANAVEX19-144 of any of claims 43-48, wherein the method uses a supercritical fluid (SCF) technique.
50. A dosage form comprising a therapeutically neuroprotective amount of the metabolite ANAVEX19-144 of any of claims 43-48.
51. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the metabolite ANAVEX19-144 of any of claims 43-48.
52. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the metabolite ANAVEX19-144 of any of claims 43-48.
53. The metabolite ANAVEX19-144 characterized by the PXRD pattern shown in FIG. 17.
54. The metabolite ANAVEX19-144 characterized by the DSC-TGA data shown in FIG. 18.
55. The metabolite ANAVEX19-144 of any of claims 53-54 characterized by particle shapes as depicted in FIG. 16.
56. The metabolite ANAVEX19-144 of any of claims 53-54 characterized by particle sizes as depicted in FIG. 16.
57. A method of making the metabolite ANAVEX19-144 of any of claims 53-56, wherein the method uses a supercritical fluid (SCF) technique.
58. A dosage form comprising a therapeutically neuroprotective amount of the metabolite ANAVEX19-144 of any of claims 53-56.
59. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the metabolite ANAVEX19-144 of any of claims 53-56.
60. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the metabolite ANAVEX19-144 of any of claims 53-56.
DESCRIPTION (OCR text may contain errors)
CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3- FURANM ETHAN AMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH
FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
FIELD
[0001] The present disclosure is directed to crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine
hydrochloride, as well as compositions, processes of preparation, and uses thereof.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM